Latest news with #healthtech
Yahoo
an hour ago
- Business
- Yahoo
PharmaSens and SiBionics to develop wearable insulin patch pump
Swiss company PharmaSens and SiBionics have entered a development partnership for niia signature, an all-in-one wearable that integrates the delivery of insulin with continuous glucose monitoring (CGM) into a compact pump. Through this device, the parties anticipate simplifying the management of diabetes for individuals who utilise insulin, aiming to minimise the daily therapy load. The wearable will leverage PharmaSens' patented platform technologies along with the biosensor capabilities of SiBionics. Both companies will offer their engineering and development know-how to bring this patch pump to the market. PharmaSens CEO Marcel Both said: 'This partnership marks a significant milestone toward realising our vision of a fully integrated, discreet, and intuitive insulin-therapy system. 'SiBionics' proven expertise in sensor technology is a perfect complement to our platform.' PharmaSens is currently developing a portfolio of three insulin patch pumps, including niia signature, designed to cater to a broad range of user needs. The range begins with the niia essential, a basal-bolus insulin pump that prioritises ease of use by minimising complexity. The niia advanced provides additional options and can be controlled through a smartphone, also allowing connection to an external CGM. PharmaSens highlights that its devices consist of one reusable part, comprising the pump and CGM electronics with a two-year lifespan, and one disposable part, which includes a 3ml insulin reservoir to extend wear time and reduce insulin waste. The company is focused on simplifying diabetes management and expanding access to insulin pump therapy. Founded in 2015, CGM technology provider SiBionics brings to the partnership its core expertise in medical device research and development, with offices in China and the US. Last year, PharmaSens submitted an application to the US Food and Drug Administration (FDA) for approval of its niia essential insulin patch pump system. "PharmaSens and SiBionics to develop wearable insulin patch pump" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Arabian Business
11 hours ago
- Health
- Arabian Business
DoH and Sanofi partner to develop new global vaccines in Abu Dhabi
The Department of Health – Abu Dhabi (DoH) and Sanofi, one of the world's leading biopharma companies, will team up to develop new global vaccines and strengthen regional capabilities in vaccine manufacturing. The two organisations signed a memorandum of understanding to this effect at the BIO International Convention 2025, in Boston, USA, recently. Dr Noura Khamis Al Ghaithi, Under-Secretary of the Department of Health – Abu Dhabi, and Laurie Gery, Global Head of Business Development, Vaccines at Sanofi, were present at the signing ceremony. DoH and Sanofi strengthen health collaboration The collaboration will leverage Abu Dhabi's health-tech ecosystem and advanced research infrastructure and Sanofi's research and development expertise. It reflects Abu Dhabi's goal to establish the emirate as a leading centre for bio- and pharmaceutical innovation. Both entities will collaborate to streamline regulatory processes, enhance manufacturing preparedness, and foster knowledge sharing among local and international experts. View this post on Instagram A post shared by دائرة الصحة – أبوظبي "DoH" (@dohsocial) Dr Asma Al Mannaei, Executive Director of the Health Life Sciences Sector at the DoH, commented: 'DoH is partnering with Sanofi to expedite the development of new global vaccines. This initiative aims to shorten the timeline from early research to public availability by utilising advanced technologies, real-time data analysis, and conducting parallel clinical trial phases. 'By combining Sanofi's global scientific expertise with Abu Dhabi's state-of-the-art infrastructure, we set new benchmarks for resilience, innovation and international partnerships. Abu Dhabi offers a globally connected, purpose-driven environment for leading research, and together we will drive a transformative change that will safeguard the health and well-being of our community while contributing to global health security.' Both organisations will advance clinical research and development planning, optimise resource allocation and establish the foundational terms for funding and access. DoH and Sanofi are collaborating in other areas as well. In 2022, the two parties agreed to work on four strategic healthcare priorities, including hematology and oncology, rare metabolic diseases, diabetes management and vaccines. Baptiste de Clarens, General Manager Greater Gulf, Vaccines, Sanofi, added: 'The Memorandum of Understanding signed with the Department of Health – Abu Dhabi marks an encouraging step towards advancing global health security while reflecting our shared interest in addressing global health challenges through scientific partnership. 'This agreement allows us to examine how Sanofi's experience in vaccine development could complement Abu Dhabi's growing R&D ecosystem. Through this initial framework, we look forward to exploring opportunities for public-private collaboration in healthcare innovation.'
Yahoo
15 hours ago
- Business
- Yahoo
AI Personal Trainer Market - Global Forecast to 2030: Explosive Growth in AI Fitness Industry: Market Set for 15.99% CAGR Through 2030
Driven by smart wearables, real-time feedback, and rising health awareness, AI trainers are reshaping fitness and rehab. Commercial and personal users adopt immersive, personalized solutions backed by tech and healthcare collaboration. AI Personal Trainer Market Dublin, June 20, 2025 (GLOBE NEWSWIRE) -- The "AI Personal Trainer Market by Product, Application, End Use - Global Forecast to 2030" report has been added to AI Personal Trainer Market grew from USD 14.48 billion in 2024 to USD 16.86 billion in 2025. It is expected to continue growing at a CAGR of 15.99%, reaching USD 35.26 billion by 2030. Opening the Door to Next-Gen AI Fitness InnovationThe rise of artificial intelligence in the fitness domain has ushered in an era where personalized workouts evolve dynamically in response to real-time biometric feedback and behavioral data. As consumers demand experiences that mirror one-on-one coaching, AI personal trainers seamlessly blend machine learning algorithms with human-centric design to craft bespoke training regimens. This convergence of data science and exercise physiology elevates adherence by delivering adaptive challenges, instant performance metrics, and motivational cues precisely when users need them shifting lifestyle patterns and heightened health awareness, market participants are racing to refine interfaces that democratize access to elite-level coaching. Voice-activated guidance, immersive virtual environments, and wearable-integrated platforms are redefining what it means to work out. In this context, established fitness brands and nimble startups alike have staked their claims, collaborating with sports scientists, hardware manufacturers, and cloud computing providers to scale solutions. Looking ahead, the foundational principles of adaptability, engagement, and measurable outcomes will continue to guide innovation, setting the stage for transformative growth across consumer and professional Reshaping the AI Personal Trainer EcosystemGlobal macro trends are propelling the AI personal training ecosystem into uncharted territory. Rapid advances in sensor miniaturization and edge computing have enabled continuous monitoring of heart rate variability, motion patterns, and muscle activation without tethering users to bulky equipment. Simultaneously, breakthroughs in natural language processing allow conversational coaching that interprets tone, pace, and context to deliver nuanced feedback and technological leaps, demographic shifts underscore the market's expansion. Aging populations in developed economies seek rehabilitation and mobility solutions, while digitally native younger cohorts embrace gamified fitness experiences that seamlessly integrate into their connected lifestyles. Healthcare ecosystems are also recognizing the promise of AI-driven interventions, incorporating remote monitoring into preventive wellness programs and chronic disease together, these developments create a fertile environment for cross-industry partnerships. Technology providers, fitness institutions, and healthcare stakeholders are uniting to establish interoperable standards, ensuring that data flows securely and insights translate into measurable health outcomes. As consumer appetites and clinical imperatives converge, the AI trainer landscape stands poised for sustained Core Market Segments Driving GrowthA multifaceted segmentation framework provides clarity on where value concentrates within the AI personal trainer domain. From a product perspective, the market divides among devices, services and software. Devices encompass a spectrum from AR/VR headsets that immerse users in virtual training environments to fitness trackers that monitor vital signs, specialized monitors for biomechanical analysis and smart watches that consolidate health metrics into a wearable form factor. Services deliver tailored coaching plans, live instructor interactions and behavioral nudges, while software platforms harness artificial intelligence to analyze historical performance data and recommend progressive load considering application, the landscape bifurcates into performance enhancement and rehabilitation. Performance enhancement solutions target athletes and fitness enthusiasts seeking to optimize strength, endurance or technique through data-driven insights. Rehabilitation platforms support recovery protocols for injury management or postoperative care, integrating sensor feedback with physiotherapy best practices. End use further differentiates between commercial use and personal use environments. Commercial deployments power corporate wellness initiatives and equip gyms with AI-enabled workout stations, whereas personal use offerings cater to individuals seeking flexible, at-home layered segmentation highlights the diverse pathways through which innovators and investors channel resources, revealing pockets of high growth potential and areas ripe for convergence between consumer convenience and clinical Regional Dynamics in the Global AI Trainer MarketRegional nuances shape demand patterns and influence strategic positioning across the AI personal trainer market. In the Americas, consumer appetite for connected fitness has accelerated with widespread adoption of smart devices and high-speed wireless infrastructure. A culture of on-demand entertainment and e-commerce integration enables seamless purchasing and trial of AI training subscriptions, driving penetration in both urban centers and suburban Europe, Middle East & Africa exhibits heterogeneous growth dynamics. Western European markets emphasize data privacy and regulatory compliance, fostering solutions that prioritize secure handling of biometric information and interoperable health records. In the Middle East and Africa, rising investments in healthcare infrastructure and digital public health initiatives provide fertile ground for pilot programs that combine AI coaching with telemedicine services, particularly in areas with limited access to in-person rehabilitation stands out as a hotbed of manufacturing excellence and rapid consumer electronics adoption. Local OEMs leverage advanced production ecosystems to introduce competitively priced wearables, while government incentives in select countries promote smart healthcare initiatives. Cross-border partnerships between technology firms and national health authorities are expanding use cases beyond fitness into preventive care, positioning the region as a bellwether for integrated AI training Players Shaping the Competitive LandscapeA cadre of leading organizations is defining today's competitive frontier. Technology giants with vast R&D budgets are embedding AI coaching modules into existing wearable ecosystems, leveraging established user bases to drive adoption. Specialist startups, often spun out of academic research labs, focus on high-precision biomechanical analysis and proprietary motion-capture innovations, securing venture capital to accelerate fitness equipment manufacturers have entered strategic partnerships with software developers to retrofit traditional gym apparatus with AI modules, creating hybrid offerings that appeal to both commercial operators and discerning home users. Consumer electronics brands, meanwhile, integrate AI trainer functionalities into flagship initiatives, bundling subscription tiers with popular hardware lines to foster stickiness and recurring revenue healthcare service providers are forging alliances with AI platform owners to deploy remote rehabilitation programs covered by insurer reimbursements, thereby expanding market reach into clinical corridors. Collaborative ecosystems spanning hardware, software and service pillars underscore a prevailing trend: success hinges on an end-to-end value proposition that seamlessly blends usability, effectiveness and data Perspectives on Future-Proofing GrowthAs the convergence of artificial intelligence and fitness accelerates, stakeholders across the value chain must remain vigilant to emerging trends and agile in their response. The trajectory of AI personal training will be shaped by ongoing advances in sensor technology, algorithmic sophistication and ecosystem interoperability, underscoring the importance of a holistic perspective that bridges hardware, software and resilience will depend on the ability to navigate regulatory shifts, foster strategic collaborations and continuously refine user experiences in pursuit of measurable health outcomes. Those who integrate clinical evidence with compelling digital interfaces will unlock the greatest long-term potential, setting new standards for engagement, efficacy and this executive summary serves as a blueprint for understanding the current state of the market and charting a course toward sustainable leadership. By harnessing data-driven insights and embracing cross-industry partnerships, organizations can position themselves at the forefront of a rapidly evolving domain where innovation and impact go hand in hand. Competitive Landscape The report categorizes to delves into recent significant developments and analyze trends in each of the following companies: Akvelon, Inc. ALFA AI GmbH Altis Movement Technologies, Inc. Apple Inc. BodBot, LLC FitnessAI Inc. Freeletics GmbH Gymfitty iFIT Health & Fitness Inc. Infosys Limited Oura Health Oy Peloton Interactive, Inc. Planfit Inc. Skynet Coaching Inc Strava, Inc. TAKELEAP DMCC Tempo, Inc. Virtuagym Whoop, Inc. Key Attributes: Report Attribute Details No. of Pages 198 Forecast Period 2025 - 2030 Estimated Market Value (USD) in 2025 $16.86 Billion Forecasted Market Value (USD) by 2030 $35.26 Billion Compound Annual Growth Rate 15.9% Regions Covered Global Key Topics Covered: 1. Preface2. Research Methodology3. Executive Summary4. Market Overview4.1. Introduction4.2. Market Sizing & Forecasting5. Market Dynamics6. Market Insights6.1. Porter's Five Forces Analysis6.2. PESTLE Analysis7. Cumulative Impact of United States Tariffs 20258. AI Personal Trainer Market, by Product8.1. Introduction8.2. Devices8.2.1. AR/VR Devices8.2.2. Fitness Trackers8.2.3. Monitors8.2.4. Smart Watches8.3. Services8.4. Software9. AI Personal Trainer Market, by Application9.1. Introduction9.2. Performance Enhancement9.3. Rehabilitation10. AI Personal Trainer Market, by End Use10.1. Introduction10.2. Commercial Use10.2.1. Corporate Wellness Programs10.2.2. Gyms10.3. Personal Use11. Americas AI Personal Trainer Market12. Europe, Middle East & Africa AI Personal Trainer Market13. Asia-Pacific AI Personal Trainer Market14. Competitive Landscape14.1. Market Share Analysis, 202414.2. FPNV Positioning Matrix, 202414.3. Competitive AnalysisFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment AI Personal Trainer Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 hours ago
- Business
- Yahoo
NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update
TORONTO and HAIFA, Israel, June 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ('NurExone' or the 'Company'), a biotech company developing exosome-based therapies for central nervous system injuries, announced today that it has been accepted into the HealthTech Hub ('HTH') Accelerator Program. Based in Boston, Massachusetts, home to more than 1,000 biotech companies1, HTH is operated by the Advanced Regenerative Manufacturing Institute ('ARMI') and its BioFabUSA initiative. NurExone's acceptance into the prestigious HTH Accelerator Program will support the Company's expansion into the U.S. market following the establishment of Exo-top Inc. ('Exo-TOP'), the Company's wholly owned U.S. subsidiary dedicated to GMP-compliant exosome manufacturing for clinical development and commercial scale-up. HTH, co-led by ARMI and Mass General Brigham, is a competitive accelerator program supported by the U.S. Department of Health and Human Services and Israel's Ministry of Health. The HTH Accelerator Program selects a limited number of innovative companies each year to help them validate U.S. clinical relevance, strengthen commercialization strategies, and build meaningful collaborations with key stakeholders across the U.S. HealthTech landscape. The program is funded by HTH at no cost to participants. Dr. Lior Shaltiel, CEO of NurExone, commented: 'The HTH Acceleration Program offers the kind of U.S.-based insight and guidance needed at this stage of our growth. As we establish Exo-TOP to manufacture clinical-grade exosomes in the U.S., the HTH will help us sharpen our regulatory and scale-up strategies and pursue meaningful commercial collaboration opportunities. This is a timely and strategic opportunity to accelerate our commercialization pathway in the world's largest healthcare market 2.' NurExone's participation in the HTH Accelerator Program is expected to enhance its visibility within the U.S. regenerative medicine ecosystem and to support its mission to bring novel exosome-based therapeutics to patients with unmet needs. Omnibus Plan Approval The Company is pleased to announce that, further to its press release dated June 4, 2025, at the Company's annual general and special meeting held on June 18, 2025 (the 'Meeting'), disinterested shareholders ratified and approved the amended and restated omnibus incentive plan (the 'Omnibus Plan'), a copy of which is available under the Company's SEDAR+ profile at The Omnibus Plan is a hybrid plan that provides flexibility to grant-equity incentive awards in the form of stock options ('Options'), restricted shares ('Restricted Shares') and restricted share units ('RSUs'). The Omnibus Plan is a hybrid 10% rolling and 10% fixed share-based compensation plan that amends and restates the Company's previous equity incentive plan approved by shareholders on June 4, 2024 (the 'Previous Plan'). The Previous Plan was a 20% fixed share-based compensation plan whereby the maximum number of common shares in the capital of the Company ('Common Shares') reserved for issuance was set at 13,166,085, representing 20% of the issued and outstanding Common Shares as of the effective date. The Omnibus Plan now includes (i) a 10% 'rolling' Option component that shall not exceed 10% of the Company's total issued and outstanding Common Shares from time to time; and (ii) a 10% fixed component permitting up to 7,800,781 RSUs and Restricted Shares in the aggregate. Additionally, the Omnibus Plan was amended to increase the number of securities issuable to insiders of the Company. The Previous Plan provided, that unless approved by disinterested shareholders, (i) the maximum number of securities issuable to insiders collectively would not exceed 10% of the Company's securities at any time and (ii) the maximum number of securities issuable to insiders collectively in any twelve-month period would not exceed 10% of the Company's total issued and outstanding securities as at the date any award was granted to an insider. Now, the Omnibus Plan provides the following that (i) the maximum number of the Company's securities issuable to insiders collectively shall not exceed 20% of the Company's total issued and outstanding Common Shares at any point in time and (ii) the maximum number of the Company's securities issuable to insiders collectively, in any 12-month period, when combined with all of the Company's other share compensation arrangements, shall not exceed 20% of the Company's total issued and outstanding securities, calculated as at the date any award is granted or issued to any insider. RSU Grants In addition, the Company announced that it has granted an aggregate of 1,125,000 RSUs to certain officers and directors of the Company pursuant to the terms and conditions of the Omnibus Plan. Each RSU vests on the one-year anniversary of the grant date and may be settled, upon their vesting, into one Common Share. The RSUs and underlying Common Shares are subject to the Exchange Hold Period (as such term is defined under the policies of the TSX Venture Exchange ('TSXV')). About NurExone NurExone Biologic Inc. is a TSXV, OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar marketsi. Regulatory milestones, including obtaining the Orphan Drug Designation, facilitates the roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy. For additional information and a brief interview, please watch Who is NurExone?, visit or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube. For more information, please contact: Dr. Lior ShaltielChief Executive Officer and DirectorPhone: +972-52-4803034Email: info@ Dr. Eva ReuterInvestor Relations – GermanyPhone: +49-69-1532-5857Email: Allele Capital PartnersInvestor Relations – +1 978-857-5075Email: aeriksen@ press release contains certain 'forward-looking statements' that reflect the Company's current expectations and projections about its future results. Wherever possible, words such as 'may', 'will', 'should', 'could', 'expect', 'plan', 'intend', 'anticipate', 'believe', 'estimate', 'predict' or 'potential' or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to: the; the Company's acceptance into the prestigious HTH Accelerator Program will support the Company's expansion into the U.S. market; the Company's participation in the HTH Accelerator Program is expected to enhance its visibility within the U.S. regenerative medicine ecosystem and support its mission as discussed herein; each RSU will be settled into one Common Share; and the NurExone platform technology offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications, including recovery of optic nerve function and overall visual health. These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including: the Company's acceptance into the prestigious HTH Accelerator Program will allow it to support the Company's expansion into the U.S. market; the Company's participation in the HTH Accelerator Program will give the Company the ability to enhance its visibility within the U.S. regenerative medicine ecosystem and support its mission as discussed herein; each RSU will be settled into one Common Share; and the NurExone platform technology offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications, including recovery of optic nerve function and overall visual health Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to: the Company's early stage of development; lack of revenues to date; government regulation; market acceptance for its products; rapid technological change; dependence on key personnel; dependence on the Company's strategic partners; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the inability to obtain or maintain regulatory approval of the drug product candidates of the Company; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the inability to obtain adequate financing; the inability to obtain or maintain intellectual property protection for the drug product candidates of the Company; risks that the Company's intellectual property and technology won't have the intended impact on the Company and/or its business; the Company's inability to carry out its pre-clinical trials and realize upon the stated benefits of the pre-clinical trials; the inability of the Company to realize on the benefits of exosomes; the inability of the Company to produce and/or supply exosomes for a wide range of applications; the inability of the Company's products to be used for patient treatment; there not being broader adoption in the field and/or cell therapy applications; the inability of the Company to fulfill its intended future plans and expectations; there not being growing clinical demand for innovative treatments in spinal cord, optic nerve, and/or other therapeutic areas; the Company's inability to realize upon the stated potential for exosome-loaded drugs in regenerating or repairing damaged nerves; the Company's inability to maintain its ongoing commitment to using its ExoTherapy platform to advance the field of regenerative medicine and/or cell therapy applications; the Company's inability to expand into further studies; the Company will not receive all required regulatory approvals; the Company will not have clinical and/or commercial breakthroughs in regenerative medicine; the Company will be unable to enhance its presence in key markets; the NurExone platform technology not offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications; the Company will not realize its future development plans, operational initiatives, and strategic objectives; the Company will not advance its therapeutic programs and clinical milestones; the Company will not engage with regulatory agencies; the Company's acceptance into the prestigious HTH Accelerator Program will not support the Company's expansion into the U.S. market; the Company's participation in the HTH Accelerator Program will not enhance its visibility within the U.S. regenerative medicine ecosystem and will not support its mission as discussed herein; each RSU will not be settled into one Common Share; and the risks discussed under the heading 'Risk Factors' on pages 44 to 51 of the Company's Annual Information Form dated August 27, 2024, a copy of which is available under the Company's SEDAR+ profile at These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law. Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. i Spinal cord injury, Glaucoma 1
Yahoo
19 hours ago
- Health
- Yahoo
Ottai Unveils Revolutionary AI-Powered Biosensor Set to Transform Chronic Disease Care
Groundbreaking Technology Empowers Patients to Take Control of Their Health HONG KONG, June 20, 2025 /PRNewswire/ -- Ottai, an Oxford-originated pioneer in AI digital health innovation, today announced the launch of its next-generation AI-powered wearable designed to revolutionize chronic disease management. This breakthrough device continuously monitors key biomarkers, leverages AI for real-time analysis and health log input, enhances patient-device interaction, and delivers personalized lifestyle recommendations. The Ottai biosensor disrupts the paradigm of traditional chronic disease monitoring—characterized by manual input, periodic lab tests, and reactive symptom management—by offering continuous monitoring paired with AI-driven automated and personalized inputs. It integrates deep learning algorithms to analyze vast amounts of real-time biomarker data and health logs, delivering actionable, tailored recommendations. The biosensor also supports intuitive voice-activated commands, allowing users to ask questions and add inputs while receiving real-time, personalized advice. "The Ottai biosensor represents a critical step toward scalable, patient-centric care," said Dr. Calvin Wang, Research Scientist at Ottai. "It represents a new era in healthcare—where we combine biosensing with AI to provide a dynamic and adaptive tool that evolves with patients' health needs and supports long-term disease management." The biosensor uses AI to power a smart health companion that supports users in real time: Real-Time Biomarker Analysis: Track critical health metrics like glucose and detect episodes of hyperglycemia and hypoglycemia continuously. The device is validated against medical gold standards and CE-approved for its accuracy and reliability. Personalized Recommendations: AI algorithms process data to suggest lifestyle, dietary, and activity adjustments, optimizing long-term health outcomes. Voice-Activated Health Logs and Lifestyle Inquiries: Interact with the biosensor via voice commands to effortlessly log health data, dietary and lifestyle habits, personalized questions, receiving real-time, actionable responses. AI-Driven Data Analysis: Advanced machine learning algorithms to analyze complex datasets, that offers users real-time insights into their health trends and risks. Seamless Integration with Other Health Apps: Syncs with other health-tracking platforms such as Apple Health and smartwatches for users' best convenience. About Ottai Ottai is a leader in empowering individuals with actionable insights to prevent and manage chronic conditions. With a mission to make chronic disease management more accessible, personalized, and proactive, Ottai aims to revolutionize the healthcare landscape with advanced, user-friendly solutions. For more information and pricing and availability of Ottai sensors, visit or contact info@ and connect with Ottai on Instagram, and Facebook. View original content to download multimedia: SOURCE Ottai Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
